Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Summary

The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML. Objectives: To determine the complete response (CR) rate, event-free survival (EFS) and overall survival (OS) of patients with newly diagnosed acute myeloid leukemia (AML) receiving standard combination chemotherapy with Idarubicin and cytarabine.

Timeline

Start

2006-12

Primary completion

2017-01

Completion

2017-01

Drugs

Indications